The lack of clarity makes choosing a company potentially confusing for patients, and the medical profession is partly to blame, said Jamy Ard, an obesity doctor and researcher at Wake Forest University School of Medicine in Winston-Salem, North Carolina
"The introduction of semaglutide 2.4 mg as the only therapy proven to reduce non-fatal myocardial infarctions in patients living with overweight or obesity without diabetes is a remarkable breakthrough
The data suggested sustained improvements at all maintenance levels, though again the greatest benefits aligned with the highest dosage
Orforglipron mimics GLP-1, a hormone your gut naturally releases after eatingthe one that tells your brain, Okay, were done here, Dr
& El-Kader, E
GLP-1s also reduce the rate at which the stomach digests food and empties, reducing appetite and make you feel fuller longer